Curis (CRIS) – Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Curis (NASDAQ: CRIS) in the last few weeks:

• 8/22/2026 – Curis was upgraded by Wall Street Zen from “strong sell” to “hold”.
• 8/17/2026 – Curis had its “buy” rating reaffirmed by HC Wainwright.
• 8/11/2026 – Curis was downgraded by Zacks Research from “hold” to “strong sell”.
• 8/8/2026 – Curis was downgraded by Wall Street Zen to “strong sell”.
• 7/24/2026 – Curis had its “buy” rating reaffirmed by HC Wainwright. They now have a $43.00 price target on the stock, up from $17.00.
• 7/17/2026 – Curis had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Curis was upgraded by Zacks Research from “strong sell” to “hold”.

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.